IMUC Up 40% On Positive Feedback From European Medical Agency for AMEX:IMUC by TradingMula

News: Phase 3 program given thumbs up for it's lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma

Like, comment or follow if you like my ideas!

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.